CA2871314A1 - Process for preparation of 17-substituted steroids - Google Patents

Process for preparation of 17-substituted steroids Download PDF

Info

Publication number
CA2871314A1
CA2871314A1 CA2871314A CA2871314A CA2871314A1 CA 2871314 A1 CA2871314 A1 CA 2871314A1 CA 2871314 A CA2871314 A CA 2871314A CA 2871314 A CA2871314 A CA 2871314A CA 2871314 A1 CA2871314 A1 CA 2871314A1
Authority
CA
Canada
Prior art keywords
compound
formula
process according
group
protecting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871314A
Other languages
French (fr)
Inventor
Erwin Schreiner
Craig E. Dixon
Boris Gorin
Qingbo LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphora Research Inc
Original Assignee
Alphora Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphora Research Inc filed Critical Alphora Research Inc
Publication of CA2871314A1 publication Critical patent/CA2871314A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

The specification relates to a process for preparation of 17-substituted steroid and intermediates useful therein. Embodiments of 17-substituted steroid have been shown as useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent5 disorders such as breast cancer.

Description

This application claims priority to and the benefit of United States Provisional Patent Application Serial Number 61/637,048 filed April 23, 2012, and Provisional Patent Application No. 61/642,253 filed May 3, 2012, the subject matter of which is incorporated herein by reference.
FIELD
[0001]
The specification relates to a process for preparation of 17-substitued steroids, and intermediates useful therein.
BACKGROUND
[0002]
Abiraterone acetate has been disclosed as an androgen biosynthesis inhibitor, and was approved and launched in the U.S. in 2011 in combination with prednisone for the oral treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel (US
5,604,213; FDA News Release 28 Apr, 2011, (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.ht in, incorporated herein by reference)). Abiraterone acetate has been commercially marketed as ZytigaTM. The structure of abiraterone acetate along with numbering of the carbon atoms is shown below.

N

9 11111110, 16 Abi raterone at_etate [0003] The published routes (US Patent Nos 5,604,213 and 5,618,807, incorporated herein by reference) toward abiraterone acetate start with dehydroepiandrosterone (DHEA) and involve manipulation of the cyclopentanone moiety to install the pyridyl group. The preferred method appears to be a Suzuki-type cross coupling reaction involving a pyridylborane and an appropriately substituted steroid, as shown below.

N
O.
? S.
y.
]=== ER2 1.*
)?
=
X. 01T or I
[0004] The known synthetic route can have certain drawbacks, such as the use of expensive reagents (triflate). In addition, the synthetic route can lead to an elimination side product, forming a double bond between the C3 and C4 position.
Further, the coupling reaction with pyridylborane utilizes a palladium (Pd) catalyst and boranes at the final synthetic step, which need to be removed from the active pharmaceutical ingredient (API), and can require column chromatographic purification. Moreover, US Patent No. 5,618,807 discloses in Example 20 that the coupling reaction leads to an impurity (16,17'-bis(steroidal) contaminant) in significant amounts (6.8% w/w), which crystallization was unsuccessful in removing. Further to the above, the compounds prepared in the process for preparation of abiraterone acetate can require column chromatography, which usually is undesirable, especially for manufacturing at industrial scale.
[0005] Hence, there is a need in the art for a process for preparation of abiraterone acetate that can avoid the use of expensive reagents, the elimination reaction, the formation of additional impurities or formation of the bis(steroidal) contaminant. In addition, there is a need in the art for a process for preparation of abiraterone acetate that can avoid or reduce the use of column chromatography.

Further, there is a need in the art for a process for preparation of abiraterone acetate, where any one of the intermediates or final product prepared is in high purity and can be purified by crystallization. Moreover, there is a need in the art for an alternate route to synthesis of 17-substituted steroids, which is suitable for large scale production.
SUMMARY OF INVENTION
[0006] In one aspect, the specification discloses a process for preparation of the compound of formula 4, the process containing the steps of:

o A r ow O. elle 510 _.
RO RO

A r Ar O.
ell. ___________________________________________ "Pi' 110411".
RO

- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;

R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;

Ar is an aryl or heteroaryl group and Ac is an acyl group.
[0007] In another aspect, the specification relates to the compound of formula 2, Ar Oe RO

wherein 10 Ar is an aryl or heteroaryl group;
R is H or an alcohol protecting group; and R' is H, an alcohol protecting group or R' together with the oxygen to which it is attached forms a leaving group.
[0008] In a further aspect, the specification relates to the compound of 15 formula 3, RO

wherein Ar is an aryl or heteroaryl group; and R is a silyl-based protecting group.
5 [0009] In a still further aspect, the specification relates to abiraterone acetate having a purity of ?950/0, 960/(:), 970/(:), -98 /0, -99 A:), 99.5% or ?99.90!o, as determined by HPLC.
[0010] In still another aspect, the specification relates to abiraterone acetate substantially free of the bis(steroidal) contaminant as determined by HPLC
analysis.
10 [0011] In still another aspect, the specification relates to the compound of formula 3 having a purity of 95%, 96%, 97%, 98%, 99 /o, 99.5% or ?99.9%, as determined by HPLC.
[0012] In another further aspect, the specification relates to the compound of formula 2 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or 15 99.9%, as determined by HPLC.

[0013] In another still further aspect, the specification relates to a process for purification of the compound of formula 3 or 4, as disclosed herein, by recrystallization of the compound of formula 3 or 4.
DESCRIPTION
[0014] A process for preparation of the compound of formula 4, the process containing the steps of:
o Pir ow O. 41111.
RO
RU

Pr Ar es Oil Sr _Jo,.
RO

- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;

- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;

Ar is an aryl or heteroaryl group and Ac is an acyl group.
[0015] The term "alcohol protecting group" as used herein is not particularly limited, and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the protecting group forms an ester, ether or is a silyl-based protecting group. In a further, embodiment for example and without limitation, the ester formed is acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv). In another embodiment, for example and without limitation, the ether protecting group formed is benzyl (Bn), 8-methoxyethoxymethyl ether (MEM), trityl (Tr), dimethoxy trityl (DMT), methoxymethyl ether (MOM), or the like. In a still further embodiment, for example and without limitation, the silyl-based protecting group formed is tert-butyldimethylsilyl (TBDMS or TBS), tri-iso-propylsilyloxymethyl (TOM), or triisopropylsilyl (TIPS).
[0016] A "leaving group" as disclosed herein is a molecular fragment or stable species that can be detached from a molecule in a bond-breaking step. The process can also involve, for example and without limitation, a bond-breaking step between the leaving group and molecule, along with formation of a double bond in the molecule. The leaving group, in accordance with the specification, is not particularly limited and should be known to a person of skill in the art or can be determined. The ability of a leaving group to depart is correlated with the pK, of the conjugate acid, with lower pKa being associated with better leaving group ability. Examples of a leaving group include, without limitation, an acyl ester or a sulfonate. Examples of sulfonates can include, without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate. In one embodiment, for example and without limitation, the leaving group is mesylate or tosylate.
[0017] The term "alkali metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali metals contain the group 1 elements of the periodic table, excluding hydrogen, and include lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and caesium (Cs). In one embodiment, for example and without limitation, the alkali metals used in accordance with the specification include lithium (Li), sodium (Na) or potassium (K). In a further embodiment, for example and without limitation, the alkali metal used in accordance with the specification includes lithium (Li).
[0018] The term "alkali earth metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali earth metals contain group 2 elements of the periodic table, and can include, for example, beryllium (Be), magnesium (Mg), calcium (Ca), Strontium (Sr), Barium (Ba). In one embodiment, for example and without limitation, the alkali earth metal used in accordance with the specification is magnesium (Mg).
[0019] The term "transition metals of group 11 or 12" should be understood by a skilled worker, and includes transition metals of group 11 or 12 of the periodic table. The transition metals of group 11 can include copper (Cu) and silver (Ag), while the transition metals of group 12 can include zinc (Zn), cadmium (Cd) and mercury (Hg).
[0020] The term "aryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "aryl" as used herein refers to any functional group or substituent derived from an aromatic carbocyclic ring.
In one embodiment, for example and without limitation, the aryl group is a C6-14 aryl.
The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
Examples of aryl include, for example and without limitation, phenyl, naphthyl, anthracenyl, and phenanthrenyl.
[0021] The term "heteroaryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "heteroaryl" as used herein refers to any functional group or substituent derived from an aromatic ring where one or more of the atoms in the aromatic ring is of an element other than carbon. In another embodiment, for example and without limitation, heteroaryl includes 5-, 6-, and 7-membered substituted or unsubstituted single-ring aromatic groups that can have one or more heteroatonns as part of the ring system.
Examples of heteroaryls include, for example and without limitation, pyridinyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, or thiophenyl. In a further embodiment in accordance with the specification, the heteroaryl group is a pyridinyl.
[0022] The term "acyl group" as used herein is not particularly limited and should be known to a skilled worker. In one embodiment, for example and without limitation, the acyl group refers to the general formula "RC(=0)-" , where R
is a hydrocarbon; and can also include the acyl protecting groups noted herein. In a further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv).
In a still further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac).
[0023] The term "hydrocarbon", as used herein, refers to a group that contains hydrogen and carbon, linked generally via a carbon backbone, but can optionally include heteroatoms. Hydrocarbyl groups include, but are not limited to alkyl, aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this specification.
[0024] The term "heteroatom", is not particularly limited and should be understood by a skilled worker. As used herein, the term means an atom of any element other than carbon or hydrogen. In one embodiment, for the example and without limitation, heteroatoms include nitrogen, oxygen, and sulfur.
[0025] The term "alkyl" as used herein is not particularly limited and should be known to a person of skill in the art; and refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. In one embodiment, for example and without limitation, the alkyl group is a C1-6 alkyl.
[0026] The term "C1_6 alkyl" in accordance with the specification is not particularly limited and should be known to a person of skill in the art. The alkyl may be, for example, and without limitation, any straight or branched alkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, n-hexyl, i-hexyl, 1,2-dimethylpropyl, methylbutyl, 1,2-dimethylbutyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-ethylbutyl, 1,3-dimethylbutyl, 2-methylpentyl or 3-methylpentyl.
[0027] The term "nucleophilic addition reaction" as used herein is not particularly limited and should be known to a skilled worker. Nucleophilic addition reaction can be considered an addition reaction where in a chemical compound a 7c-bond is removed by creation of two new a-bonds by the addition of a nucleophile.
The term "nucleophile" as used herein is not particularly limited and should be known to a skilled worker. Nucleophile can be considered as a species that donate an electron-pair to an electrophile to form a chemical bond in a reaction. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles. The term "electrophile" is also not particularly limited and should be known to a skilled worker. An electrophile (literally electron-lover) can be considered as a reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile.
[0028] In the process as disclosed herein, "Ar" in the compound Ar-M
can act as the nucleophile, while carbonyl carbon can act as the electrophile. Without being particularly limited, various embodiments of the compound Ar-NI can be used so long as the nucleophilic addition of Ar to the carbonyl carbon can take place.
In one embodiment, the term Ar-M can include, for example and without limitation, 3-pyridinyl lithium, phenyl magnesium bromide or 3-pyridinyl magnesium bromide.
In a further embodiment, for example and without limitation, the term Ar-M can include 3-pyridinyl lithium.
[0029] The term "dehydrating a compound", as used herein is not particularly limited and should be known to a skilled worker. A dehydration reaction can be considered as an elimination reaction that involves the loss of water, or analogue, from the reacting molecule, and which can lead to formation of an additional bond.
The method of performing the dehydration reaction is not particularly limited.
In one embodiment, for example and without limitation, the dehydration reaction is carried out using an acid or a base.
[0030] The term "acid" as used herein is not particularly limited and should be known to a skilled worker. An acid can be considered as a substance that can act as a proton donor (Bronsted-Lowry acid) or an electron pair acceptor (Lewis acid).
In one embodiment, the acid used in the process disclosed herein is, for example and without limitation, hydrochloric acid (HCI), hydrobromic acid (H Br), acetic acid (CH3CO2H), sulfuric acid (H2SO4) or p-toluenesulfonic acid (p-TSA).
[0031] The term "base" as used herein is not particularly limited and should be known to a skilled worker. A base can be considered as a substance that can accept hydrogen ions (protons) or donate an electron pair. In one embodiment, the base used in the process disclosed herein is, for example and without limitation, triethylamine (TEA), N,N-diisopropylethylamine, (DIPEA), 1,8-diazabicycloundec-ene (DBU), sodium tert-butoxide (t-BuONa), potassium tert-butoxide (t-BuOK), lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS), potassium bis(trimethylsilyl)amide (KHMDS) or lithium tetramethylpiperidide (LiTMP). In a further embodiment, for example and without limitation, the base used in the process disclosed herein is triethylamine (TEA).
[0032] The step of deprotecting the compound of formula 3 as disclosed herein can be optional depending upon the substituents present. Further, the step of deprotection is not particularly limited and should be known to a skilled worker or can be determined. The method of carrying out the deprotection step can depend upon the substituent. In one embodiment, for example and without limitation, deprotection is carried out using an acid. The acid used for deprotection is not particularly limited and should be known to a skilled worker or can be determined. Examples of an acid include acids as are described herein.
[0033] In another embodiment, the step of deprotection is carried out, for example and without limitation, using a fluoride source. The fluoride source is not particularly limited and should be known to a skilled worker or can be determined.
In one embodiment, for example and without limitation, the fluoride source is sodium fluoride (NaF), tetra-butyl ammonium fluoride or pyridine hydrofluoride (HF-Py). The step of deprotection using a fluoride source can be carried out, for example, when the protecting group is a silyl-based protecting group, as described herein.
[0034] The step of acylating the compound of formula 3 as disclosed herein can be optional depending upon the substituent present. As used herein, acylation can be considered as the process of adding an acyl group to a compound.
Further, the step of acylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acylation involves acetylating the compound of formula 3, where R is H. The process of acetylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acetylation is carried out using acetic anhydride (Ac20) or acetyl chloride (AcCI), in the presence of base. The base used is not particularly limited and can include one of the bases as noted herein.
[0035] Referring to Scheme 1 shown below, an embodiment of the process as disclosed herein is further described.
Step2 N
o Stepl / 'N

Oe TBSCI
_,,..
Et3N
le*
_J.-Br Oe OH
Ole DMAP
HO
DMF O. n BuLi Ole TBSO

la lb 2b 1 MsCI Step3 Et3N
/ 'N SteP4 DCM / \
N
/ \ N Step6 HO
-..(-Di axed e 0140 Pyridi ne OS
O
HO TBSO
Ac0 4 3c 3b Scheme 1 [0036]
Step 1 involves protecting the hydroxyl group of compound of formula la to form the compound of formula lb. The protecting group used is a silyl-based protecting group, and is tert-butyldimethylsilyl (TBS), although other protecting groups, including other silyl-based protecting groups can be used. The use of the silyl-based protecting group, such as the tert-butyldimethylsilyl (TBS), can avoid generation of or reduce the amount of the impurity having a double bond at the C3-C4 position. As noted above, the impurity having a double bond between the C3-C4 position can be formed in an elimination reaction, for example in the presence of a base, where, for example, an acetate (leaving group) at the C3 position is removed and a double bond formed. Upon completion of the reaction, the reaction mixture can be quenched using water, which can allow precipitation of the solid product that can be separated by filtration.
[0037] Nucleophilic addition reaction of the compound of formula lb with pyridinyl lithium in step 2, leads to formation of the compound of formula 2b.

Other pyridinyl-metal complexes can be used for nucleophilic addition. These include, for example and without limitation, pyridinyl-magnesium, pyridinyl-cuprate or pyridinyl-zinc reagent. The use of pyridinyl lithium can help avoid use of more toxic metals and can provide cleaner and safer reaction conditions.
[0038] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the nucleophilic reaction can vary.
The solvent used in the nucleophilic reaction in Step 2 of Scheme 1, can include, for example, toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 2, as shown in Scheme 1, is toluene.
[0039] The temperature for carrying out the nucleophilic coupling reaction can also vary. Temperatures for the nucleophilic coupling reaction can range from low temperatures, such as, for example and without limitation, -80 C to higher temperatures, such as, for example and without limitation, 50 C. In one embodiment, the temperature for carrying out the nucleophilic addition reaction, as shown in Step 2 of Scheme 1, is from -80 C to 25 C, and values in between. In another embodiment, the temperature can range from -80 C to 0 C, -75 C to -10 C, -70 C to -20 C, -70 C to -40 C or -70 C to -60 C.
[0040] Upon completion, the reaction can be quenched using an aqueous solution, which can include, for example and without limitation, brine.
Extraction and evaporation of the organic layer can provide crude compound 2b. Crude compound 2b can be triturated with an organic solvent to provide compound 2b that can be used in subsequent process steps without further purification. The solvent used for trituration can vary. In one embodiment, in the process step 2 as shown in Scheme 1 above, trituration was performed using acetonitrile.
[0041] The hydroxyl group formed in step 2 can be converted into a leaving group in step 3, by reaction with mesyl chloride to form a mesylate, which can then undergo a dehydration reaction in the presence of a base to form compound 3b.
The leaving group formed can vary and different leaving groups can be used for the elimination reaction to form the double bond. In one embodiment, the hydroxyl group is converted into a sulfonate-based leaving group, which can include, for example and without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate, as noted above. In another embodiment, as shown in Scheme 2 below, dehydration of the alcohol is performed in the presence of an acid, where H20 forms the leaving group. The sulfonate-based leaving groups can form good leaving groups and can help in improving the overall elimination reaction to form the double bond. In a further embodiment, the sulfonate-based leaving group is a mesylate.
[0042] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the dehydration reaction can vary.
The solvent used in the nucleophilic reaction in Step 3 of Scheme 1, can include, for example, dichloromethane (DCM), toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 3, as shown in Scheme 1, is dichloromethane (DCM).
[0043] The temperature for carrying out the dehydration reaction can also vary. Temperatures for the dehydration reaction can range from temperatures as low as, for example and without limitation, -40 C to higher temperatures, such as, for example and without limitation, 200 C, and can depend upon the leaving group.
In one embodiment, the temperature for carrying out the dehydration reaction, as shown in Step 3 of Scheme 1, is from -40 C to 50 C, and values in between. In another embodiment, the temperature can range from -20 C to 40 C, -15 C to C, -10 C to 25 C, 0 C to 25 C or 5 C to 25 C. In the embodiment shown in step 3 of Scheme 1, the reaction is initially performed at about 5 C and then allowed to continue at about 25 C.
[0044] Deprotection of compound 3b using an acid leads to compound 3c (Step 4). Step 5 involves acylation of the compound 3c using acetic anhydride to form compound 4. The reaction mixture can be quenched with an aqueous solution, for example water, to precipitate compound 4, which can be separated by filtration. Following the process as outlined in Scheme 1, compound 4 having purities of about 95% or greater can be achieved. Moreover, the process can avoid formation of the bis(steroidal) impurity that can be difficult to separate by purification.
[0045] Further to the above, methods of crystallization of compound 4 have been determined that can assist with purification and avoid use of column chromatography. Different solvent and solvent mixtures have been tested. In one embodiment, for example, the solvent system used for recrystallization is methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes or acetonitrile/water. In a further embodiment, different ratios of the solvent system have been determined for recrstallization. For example, methanol or ethanol was used for recrystallization from about 3 to 10 parts v/w and values in between like about 4 to 6 parts v/w or about 5 parts v/w. For solvent mixture systems, the ratio of the solvents can vary. For example, toluene/heptanes mixtures of about 0.5/3 v/v or about 1/2 v/v parts can be used; and for acetonitrile/water, mixtures of about 8/1 v/v, about 7/1, about 6/1 or about 5/1 parts can be used. In a further embodiment, the compound of formula 4 can be recrystallized using ethanol (5 v/w part) to provide a product having 98% purity or more, as disclosed herein, and lacking any bis(steroidal) contaminant. Further optimization using solvent and scale can improve purity.
[0046] The term "recrystallization" as used herein is not particularly limited and should be known to a skilled worker. The term "recrystallization" as used herein refers to a technique used to purify chemical compounds. The process can be carried out by dissolving both impurities and a compound in an appropriate solvent, either the desired compound or impurities can be coaxed out of solution, leaving the other behind. In the process disclosed herein, the compound of formula 3 or 4, along with impurities, is dissolved in the relevant solvent.
Dissolution can take place at elevated temperatures, including at the boiling point of the solvent used. This solvent is allowed to cool and crystallization of the compound of formula 3 or 4 to take place, followed by collection of the crystals.
[0047] Scheme 2, shown below, discloses alternate embodiments of carrying out the process for preparation of the compound of formula 4 in accordance with the specification, and where different R groups can be present and the reaction can be carried out in the presence or absence of a protecting group.
[0048] Scheme 2 also discloses alternative methods for carrying out the elimination reaction. For example, compound of formula 2c can be converted to the compound of formula 3c by use of an acid. The acid used in not particularly limited, and can include, for example and without limitation, hydrochloric acid, para-toluenesulfonic acid (PTSA) or acetic acid (AcOH). In a further embodiment, the acetylation and elimination reaction can be carried out concurrently by reaction of the compound of formula 2c with acetic anhydride to form compound of formula 4.
/ \ N\
/ N
MsCI
Et3N
110. DCM
Oil ROSS ROSS
SO SO
R=TBS 2b R=TBS 3b N

O. B Ha r Dioxane 010 nB.ILi r RO / \ N / \ N
R=H, Po, T I Ha or 1 O. OH TpsA

50 Ole HD HO
2c 3c Ao20 1 Ac20 pyricine pyridne / \ N \
/ N
OH [Visa 01 Et3Nm Oil O. Ole Pc0 ADO
2d 4 Scheme 2 [0049] The organic solvent used in the reactions described herein is not particularly limited and should be known to a person of skill in the art or can be determined. The particular solvent used would depend upon the reactants and the reaction being carried out, to allow the reaction to proceed. Similarly, the reaction temperature used in the process steps disclosed herein is not particularly limited and should be known to a skilled worker or can be determined. The reaction temperature can depend upon a number of factors including reagents, solvent and presence of catalyst.
[0050] The process as disclosed herein can lead to different intermediates that can be useful for the preparation of the compound of formula 4.
Therefore, in another aspect the specification discloses compounds of formula 2, where Ar is an aryl group, R is H or an alcohol protecting group and R' is H, an alcohol protecting group or Rl together with the oxygen to which it is attached forms a leaving group.
Ar Oe RO

10 [0051] In a further aspect, the specification relates to the compound of formula 3, where Ar is an aryl group; and R is a silyl-based protecting group.
Ar OB

RO
[0052] In a still further aspect, the specification relates to abiraterone acetate having a purity of 95 /o, 96 /o, 97 /o, 193 /o, 1919 /o, 199.5% or 99.9%, as determined by HPLC. Further, the specification discloses abiraterone acetate being substantially free of the bis(steroidal) contaminant.
[0053] In still another aspect, the specification relates to the compound of formula 3 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or ?99.9%, as determined by HPLC.
[0054] In another further aspect, the specification relates to compound of formula 2 having a purity of ?950/0, ?960/0, 970/(:), 980/(:), 99%, 99.5% or 199.9 /0, as determined by HPLC.
EXAMPLE EMBODIMENTS
[0055] Disclosed herein below are example embodiments of the specification, which are not intended to be limiting of the invention as described and claimed herein.
[0056] EXAMPLE 1: Compound lb [0057] A 250 ml three necks round bottom flask equipped with a magnetic stirrer, thermometer and nitrogen inlet was charged with compound la (60g 208mmole), dimethylformamide (DMF) (600m1), tert-butyldimethylsilyl chloride (TBSCI) (38g 250mmol), N,N-dimethylamino pyridine (DMAP) (5g 42mmole) and triethylamine (Et3N) (32g, 312nnmol). The suspension is stirred 24 hr. TLC
analysis indicated the depletion of compound la (Hep: Et0Ac 1:1 AMCS). The reaction mixture is poured in water (3L) and agitated for 1.5hr. The solid product is collected by filtration and washed with water (2L) and dried at high vacuum at 45 C for hour to give 83g of compound lb off white solid (Quantitative yield). NMR
confirmed structure.
[0058] EXAMPLE 2: Compound 2b [0059] A 500 ml three neck round bottom flask equipped with a magnetic stirrer, thermometer and nitrogen inlet was charged with 3-bromopyridine (19.6g 124mmol) and toluene (100 ml). The solution was cooled to -65 C. With agitation, 2.5M n-butyl lithium (nBuLi) in hexanes (5oml, 124mmol) was charged while maintaining a temperature of reaction less than -60 C. The mixture was then agitated at same temperature for 1.5 hours. Charged with a solution of compound lb (5g, 12.4mmol) in toluene (100 ml). The brown reaction mixture was agitated at for -65 C 1 hour. TLC analysis indicated formation of compound 2b (Hep:Et0Ac 1:1 UV, AMCS) The mixture was quenched with the mixture of 12% of NaC1 solution (200m1). The reaction mixture was warm to10 C. The mixture was extracted with 200m1 of methy tert-butyl ether (MTBE). Organic layer was separated and concentrated to dryness. The crude was triturated with acetonitrile (100m1). Solid product was collected by filtration and washed with acetonitrile (40m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 2b as an off white solid 4.7g (79% yield). NMR and MS confirmed structure.
[0060] EXAMPLE 3: Compound 3b [0061] A 250 ml three neck round bottom flask with a magnetic stirrer and nitrogen inlet was charged with compound 2b (4.5g, 9.3 mmol) and dichloromethane (DCM) (90 ml). The solution was cooled to 5 C. With agitation, triethylamine (Et3N) (9.5g 93mmol) and mesyl chloride (MsC1) (5.4g 47mmol) was charged. The mixture was then agitated at same temperature for 1 hour and ambient temperature for 1 hour. TLC analysis indicated the depletion of compound 2b (Et0Ac UV and AMCS). The reaction solution was quenched with sat NaHCO3.
Separated organic is dried with MgSO4 and separated and concentrated to dryness.
The crude was purified with silica gel (100g) with Biotage. Eluted with ethyl acetate (Et0Ac) and Heptane 10% to 50%. Pure fraction was collected and concentrated to dryness to give compound 3b as a white solid 3g (69% yield). NMR and MS
confirmed structure.
[0062] EXAMPLE 4: Compound 3c [0063] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3b (2.5g, 5.4 mmol), 1,4-dioxane (25 ml), methanol (Me0H) (12.5m1) and HC14M in 1,4-dioxane (5.4 ml 22mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. Continue agitating for 1 hour the solution was turn to suspension.
The mixture was then agitated for another 3 hours. TLC analysis indicated the depletion of compound 3b (Hep:Et0Ac 1:1 UV and AMCS). The solution concentrated to dryness. The crude was triturated with 1,4-dioxane(25m1) for lhour. The solid product was collected by filtration and washed with 1,4-dioxane (10m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 3c as a white solid 2.1g (quantitative yield). NMR and MS confirmed structure.
[0064] EXAMPLE 5: Compound 4 [0065] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3c (2.0g, 5.7 mmol), pyridine (20m1) and acetyl anhydride (2.7 ml 29mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. The reaction solution was then agitated for another 1.5 hours. TLC analysis indicated the depletion of compound 3c (Et0Ac UV and AMCS). The reaction solution was quenched with water (40m1) at ice bath. The temperature was remained under 15 C. After quench, the white solid product was precipitated out. The mixture was agitated at ice bath for 2 hours. The solid product was collected by filtration and washed with water (20m1) and dried at high vacuum oven at 45 C for 72 hours to give compound 4 a white solid 1.9g (85% yield, 95% purity by HPLC). NMR and MS
confirmed structure.
[0066] EXAMPLE 6: Purification of Compound 4 by crystallization [0067] Charge a round bottom flask with 1.0 g of compound 4 and 5 to 10 mL
of ethanol. With agitation, heat the mixture to reflux until clear solution is attained.
Cool the solution gradually to 0 -25 C. Collect crystallized product by filtration, dry under nitrogen flow until constant weight is achieved. HPLC analysis indicates purity of 98%.
[0068] EXAMPLE 7: Preparation of compound lb o o te MSG/ DMF
.._ opie Et3N O.
HO TBSO
la lb [0069] A 1L three necks round bottom flask equipped with a over head stirrer, thermometer and nitrogen inlet was charged with compound la (50g, 173mmole), tert-butyl dimethyl silyl chloride (TBSCI) (31.4g 208mmol), dimethylformamide (DMF) (375m1) and triethylamine (Et3N) (26g, 260mmol). The suspension is heated up to 50 C, stirred 3 hr. HPLC analysis indicated the depletion of compound la.
The reaction mixture was cooled to 5 C and quenched the reaction mixture with water (375 ml). The temperature of the mixture was raised to 15 C and then agitated at ambient temperature for 2hr. The solid product is collected by filtration and washed with water (750m1) and dried at high vacuum at 45 C for 24 hour to give 69g of compound lb off white solid (99% yield). NMR confirmed structure.
[0070] EXAMPLE 8: Preparation of compound 2b N

OH
0.O. Br O. nBuLifTd uene O.
TBSO TBSO
1b 2b [0071] A 2L three neck round bottom flask equipped with a overhead stirrer, thermometer, dropping funnel and nitrogen inlet was charged with toluene (500 ml) and cooled to -65 C. With agitation, 2.5M n-butyl lithium (nBuLi) in hexanes (225m1, 550mmol) was charged while maintaining a temperature of reaction less than -60 C. Addition took 50 min. Then 3-bromopyridine (59g 373mmo1) in toluene (100 ml) was charged over 2 hr. The solution was agitated at -65 C for 0.5 hr.

Prepared a solution of compound lb (50g, 124mmol) in toluene (400 ml) and charged to the reaction solution over 2 hr. The light brown reaction mixture was agitated at for -65 C 0.5 hour. TLC analysis indicated formation of compound 2b (Hep:Et0Ac 1:1 UV, AMCS) The mixture was warmed up to -35 C and quenched with the water (500m1). The reaction mixture was then warm to10 C. Organic layer was separated and the aqueous is extracted with toluene (500m1).
Combined organic was washed with water (500m1). Separated organic layer was concentrated to 250 ml. Charged with heptane (750m1). The mixture was concentrated to 250 ml and then charged with heptane (750m1). Repeated this procedure for another time. At the last, to the 250 ml mixture, charged with heptane (250m1). The mixture was agitated at ambient temperature for 1 hr. Solid product was collected by filtration and washed with heptane (150m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 2b a off white solid 46g (77% yield). NMR
and MS confirmed structure.
[0072] EXAMPLE 9: Preparation of compound 4a - N
/ \ N
CH
O.1) MsCI, Et3N, EX
_______________________________________________ 0- O.
50 2) Conc HO/THF O.
TESO HO
2b 3c / \ N
4c20 ______________________ >
Pyridine O.
O.
Pc 4a [0073] A solution of compound 2b (200 g, 415mmol, 1 equiv) in CH2Cl2 (DCM) (1600 mL, 8 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was flushed with nitrogen (N2) for 5 min. The solution was cooled to 5 C and triethyl amine (578.5 mL, 4151mmol, 10 equiv) was added slowly over 30 min and was stirred at 5 C for 15 minutes. Then mesyl chloride (MsCI) (161.3 mL, 2075 mmol, 5 equiv) was added drop wise over 45 min by controlling the temperature below12 C. The reaction mixture was then stirred at 5 C for 1.5 -h. The ice-bath was removed and the reaction mixture was stirred to room temperature for 12 h. DI water (600 mL 3 parts) was added to the reaction mixture and stirred for 30 minutes, separated out the DCM layer. The DCM layer is then washed with DI water (600 mL, 3 parts) and was concentrated on a rotovap (bath @35 C) down to 1000 mL (5 parts). Then solvent exchanged to tetrahydrofuran (THF) by charging THF (2x2000 mL, 10 parts each) and concentrated to 1000 mL
(5 parts).The concentrated reaction mixture was transferred into a 5L 3-neck round-bottom flask equipped with a dropping funnel. Charged THF (2000 mL, 10 parts) at room temperature and slowly added concentrated hydrochloric acid (76 mL, 2.2 equiv) from the dropping funnel over lhour. Agitated the reaction mixture (light-brown suspension) at room temperature for 2 hours and was filtered.
Washed with THF (2x1000 mL, 5 parts each). Dried the solids at room temperature under suction with nitrogen atmosphere to afford compound 3c (170.3 g).
[0074] To a suspension of compound 3c (170 g, 440.8 mmol) in pyridine (680 mL, 4 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was added acetic anhydride solution (208.5 mL, 2204 mmo1,5 equiv) at room temperature slowly from an addition funnel over 30 minutes. The mixture was stirred at room temperature for 4 h. Cooled the reaction mixture to 50C and D.I.
water (1700 mL, 10 parts) was added slowly by controlling the temperature below C. Agitated the reaction mixture at 5 C for 3 h and the solids were filtered, washed with DI water (2x 850 mL, 5 parts each) and dried at room temperature 15 under suction for 18 h and then in a vacuum oven at 450C under vacuum for 24 h to afford crude compound 4a (140.2 g).
[0075] EXAMPLE 10: Recrystallization of compound 4a [0076] 5g of the crude compound 4 (where Ar is 3-pyridinyl) was dissolved in isopropanol (IPA) (100 mL, 20 parts) and was filtered through a celite pad, washed the celite pad with IPA (15 mL, 3parts). The filtered IPA solution of compound 4 is then passed through a carbon cartridge filter (SUPRACAP AKS-1 60D, PALL
FILTER).
Washed the carbon filter with IPA (75mL, 15 parts). Combined all the IPA
filtrates and washes and was concentrated to 30 mL (6 parts) on a rotovap (bath@40 C).
Charged DI water 30mL (6 parts) and heated the reaction mixture to 80 C to dissolve all the solids and maintained for 1 h at 80 C. Then cooled to room temperature and maintained for 12 h and then cooled to 5 C and maintained for h. The white solids were filtered, washed with 1:1 IPA/water mixture (10 mL, 2 parts) and dried in a vacuum oven at 450C under vacuum for 24 h to afford pure compound 4a (3.34 g). HPLC analysis indicates purity of 99.7%.
EMBODIMENTS
[0077] 1. A process for preparation of the compound of formula 4, the process comprising:
0 Ar ORi lee O.
OS _Jo.. OpOp RO RO

Ar Ar SO SO
RO MO

[0078] nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
[0079] dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
[0080] optionally, deprotecting the compound of formula 3; and [0081] optionally, acylating the compound of formula 3 to form the compound of formula 4, [0082] wherein [0083] R is H or an alcohol protecting group;
[0084] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
[0085] M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
[0086] Ar is an aryl group and [0087] Ac is an acyl group.
[0088] 2. The process according to embodiment 1, wherein Ar is a heteroaryl group.
[0089] 3. The process according to embodiment 1, wherein Ar is pyridinyl.
[0090] 4. The process according to embodiment 1, wherein Ar is 3-substituted pyridinyl.
[0091] 5. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group.
[0092] 6. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is acetyl.
[0093] 7. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is a silyl-based protecting group.
[0094] 8. The process according to embodiment 7, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[0095] 9. The process according to any one of embodiments 1 to 8, wherein M is alkali metal.
[0096] 10. The process according to embodiment 9, wherein the alkali metal is Li.
[0097] 11. The process according to any one of embodiments 1 to 10, wherein R1 is H.
[0098] 12. The process according to any one of embodiments 1 to 10, wherein RI- together with the oxygen to which it is attached forms a leaving group.
[0099] 13. The process according to any one of embodiments 1 to 10, wherein RI- together with the oxygen to which it is attached forms a leaving group and the leaving group is nnesylate or tosylate.
[00100] 14. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of an acid.
[00101] 15. The process according to embodiment 14, wherein the acid is hydrochloric acid (HCI) or p-toluene sulfonic acid (pTSA).
[00102] 16. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of a base.
[00103] 17. The process according to embodiment 16, wherein the base is triethylamine (TEA).
[00104] 18. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in the presence of an acid.
[00105] 19. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in using a fluoride source.
[00106] 20. The process according to any one of embodiments 1 to 19, wherein the step of acylating comprises acetylating the compound of formula 3.
[00107] 21. The process according to any one of embodiments 1 to 20, wherein the process comprises forming the compound of formula 4a .----N
\ /
OB
O.

o--) 4a .
[00108] 22. The compound of formula 2, Ar OR' Oe RO

[00109] wherein 5 [00110] Ar is an aryl group;
[00111] R is H or an alcohol protecting group; and [00112] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
[00113] 23. The compound of embodiment 22, wherein Ar is pyridinyl.
10 [00114] 24. The compound of embodiment 23, wherein the compound of formula 2 is a compound of formula 2a / \N
OR' Oe ROSS
2a [00115] 25. The compound of any one of embodiments 22 to 24, wherein Rl is H.
[00116] 26. The compound of any one of embodiments 22 to 24, wherein together with the oxygen to which it is attached forms a leaving group.
[00117] 27. The compound of any one of embodiments 22 to 26, wherein R
is acetyl.
[00118] 28. The compound of any one of embodiments 22 to 26, wherein R
is a silyl-based protecting group.
[00119] 29. The compound of formula 3, Ar O.

RO

[00120] wherein [00121] Ar is an aryl group; and [00122] R is a silyl-based protecting group.
[00123] 30. The compound of embodiment 29, wherein Ar is pyridinyl.
[00124] 31. The compound of embodiment 29 or 30, wherein the compound is the compound of formula 3a .---N
\/
0.
RD O.
3a .
[00125] 32. The compound of any one of embodiments 29 to 31, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[00126] 33. Abiraterone acetate having a purity of ?95 /0, 96 /0, 97 /0, 198 /0, 199 /0, 199.5% or 199.9(:)/0, as determined by HPLC.
[00127] 34. The compound of formula 3 having a purity of 950/c), 9E.cYc), ?97%, ?98%, ?99c)/0, ?99.5% or ?99.9%, as determined by HPLC.
[00128] 35. The compound of formula 2 having a purity of 95 /c), 96 /(:), 97c1/0, 98c)/0, 99 /0, 99.5% or 99.9%, as determined by HPLC.
[00129] 36. A process for purification of the compound of formula 3 or 4, Ar A r O.

ROSS

At 1:30 4 [00130] wherein R is H or an alcohol protecting group; Ar is an aryl or heteroaryl group and Ac is an acyl group;
[00131] the process containing the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
[00132] 37. The process of embodiment 36, wherein the solvent is methanol, ethanol or isopropanol.
[00133] 38. The process of embodiment 37, wherein the solvent used is 3 to 10 parts v/w of the compound of formula 3 or 4.
[00134] 39. The process of embodiment 36, wherein the solvent is isopropanol/water, toluene/heptanes and acetonitrile/water.
[00135] 40. The process of embodiment 39, wherein the solvent is toluene/heptanes and the solvent used is 0.5/3 to 1/2 parts v/w of the compound of formula 3 or 4.
[00136] 41. The process of embodiment 39, wherein the solvent is acetonitrile/water and the solvent used is 8/1 to 5/1 parts v/w of the compound of formula 3 or 4.
[00137] 42. The process of embodiment 39, wherein the solvent is isopropanol/water and the solvent used is 0.5/3 to 2/1 parts v/w of the compound of formula 3 or 4.
[00138] 43. The process of any one of embodiments 36 to 42, wherein the compound of formula 3 or 4 has a purity of 98 /0, as determined by HPLC.
[00139] Certain adaptations and modifications of the described embodiments can be made. Therefore, the above discussed embodiments are considered to be illustrative and not restrictive.

Claims (43)

1. A process for preparation of the compound of formula 4, the process comprising:
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;

Ar is an aryl or heteroaryl group and Ac is an acyl group.
2. The process according to claim 1, wherein Ar is a heteroaryl group.
3. The process according to claim 1, wherein Ar is pyridinyl.
4. The process according to claim 1, wherein Ar is 3-substituted pyridinyl.
5. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group.
6. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is acetyl.
7. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is a silyl-based protecting group.
8. The process according to claim 7, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
9. The process according to any one of claims 1 to 8, wherein M is alkali metal.
10. The process according to claim 9, wherein the alkali metal is Li.
11. The process according to any one of claims 1 to 10, wherein R1 is H.
12. The process according to any one of claims 1 to 10, wherein R1 together with the oxygen to which it is attached forms a leaving group.
13. The process according to any one of claims 1 to 10, wherein R1 together with the oxygen to which it is attached forms a leaving group and the leaving group is mesylate or tosylate.
14. The process according to any one of claims 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of an acid.
15. The process according to claim 14, wherein the acid is hydrochloric acid (HCI) or p-toluene sulfonic acid (pTSA).
16. The process according to any one of claims 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of a base.
17. The process according to claim 16, wherein the base is triethylamine (TEA).
18. The process according to any one of claims 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in the presence of an acid.
19. The process according to any one of claims 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in using a fluoride source.
20. The process according to any one of claims 1 to 19, wherein the step of acylating comprises acetylating the compound of formula 3.
21. The process according to any one of claims 1 to 20, wherein the process comprises forming the compound of formula 4a
22. The compound of formula 2, wherein Ar is an aryl group;
R is H or an alcohol protecting group; and R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
23. The compound of claim 22, wherein Ar is pyridinyl.
24. The compound of claim 23, wherein the compound of formula 2 is a compound of formula 2a
25. The compound of any one of claims 22 to 24, wherein R1 is H.
26. The compound of any one of claims 22 to 24, wherein R1 together with the oxygen to which it is attached forms a leaving group.
27. The compound of any one of claims 22 to 26, wherein R is acetyl.
28. The compound of any one of claims 22 to 26, wherein R is a silyl-based protecting group.
29. The compound of formula 3, wherein Ar is an aryl group; and R is a silyl-based protecting group.
30. The compound of claim 29, wherein Ar is pyridinyl.
31. The compound of claim 29 or 30, wherein the compound is the compound of formula 3a
32. The compound of any one of claims 29 to 31, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
33. Abiraterone acetate having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
34. The compound of formula 3 or 3a having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
35. The compound of formula 2 or 2a having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
36. A process for purification of the compound of formula 3 or 4, wherein R is H or an alcohol protecting group; Ar is an aryl or heteroaryl group and Ac is an acyl group;
the process comprising the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
37. The process of claim 36, wherein the solvent is methanol, ethanol or isopropanol.
38. The process of claim 37, wherein the solvent used is 3 to 10 parts v/w of the compound of formula 3 or 4.
39. The process of claim 36, wherein the solvent is isopropanol/water, toluene/heptanes and acetonitrile/water.
40. The process of claim 39, wherein the solvent is toluene/heptanes and the solvent used is 0.5/3 to 1/2 parts v/w of the compound of formula 3 or 4.
41. The process of claim 39, wherein the solvent is acetonitrile/water and the solvent used is 8/1 to 5/1 parts v/w of the compound of formula 3 or 4.
42. The process of claim 39, wherein the solvent is isopropanol/water and the solvent used is 0.5/3 to 2/1 parts v/w of the compound of formula 3 or 4.
43. The process of any one of claims 36 to 42, wherein the compound of formula 3 or 4 has a purity of >=98%, as determined by HPLC.
CA2871314A 2012-04-23 2013-04-22 Process for preparation of 17-substituted steroids Abandoned CA2871314A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637048P 2012-04-23 2012-04-23
US61/637,048 2012-04-23
US201261642253P 2012-05-03 2012-05-03
US61/642,253 2012-05-03
PCT/CA2013/050311 WO2013159225A1 (en) 2012-04-23 2013-04-22 Process for preparation of 17-substituted steroids

Publications (1)

Publication Number Publication Date
CA2871314A1 true CA2871314A1 (en) 2013-10-31

Family

ID=49482082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871314A Abandoned CA2871314A1 (en) 2012-04-23 2013-04-22 Process for preparation of 17-substituted steroids

Country Status (3)

Country Link
EP (1) EP2841444A4 (en)
CA (1) CA2871314A1 (en)
WO (1) WO2013159225A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877482A4 (en) * 2012-07-25 2016-04-06 Mapi Pharma Ltd Process and intermediates for the preparation of abiraterone acetate
US9937259B2 (en) * 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN105503992A (en) * 2016-01-22 2016-04-20 江苏联环药业股份有限公司 Preparation method of abiraterone acetate
CN107722101A (en) * 2017-11-03 2018-02-23 郑州大学 Steroidal pyridine derivatives and its preparation method and application
WO2020180942A1 (en) 2019-03-06 2020-09-10 Propella Therapeutics, Inc. Abiraterone prodrugs
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938030A (en) * 1956-10-03 1960-05-24 Ciba Pharm Prod Inc New steroids substituted by a heterocyclic nitrogen-containing ring in 17-position
CA2132449C (en) * 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
NZ273367A (en) * 1993-09-30 1997-07-27 British Tech Group Preparation of 3<beta>-hydroxy (or lower acyloxy)-16,17-ene-17-(2-pyridyl)-substituted steroids using a palladium complex catalysed cross coupling reaction
CN101768199B (en) * 2009-12-24 2014-03-26 深圳万乐药业有限公司 Polymorphs of abiraterone acetate and preparation method thereof
CN102321142A (en) * 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 Abiraterone acetate crystal form and preparation method thereof
EP2607371A1 (en) * 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Processes for the preparation of abiraterone and related compouds
EP2877482A4 (en) * 2012-07-25 2016-04-06 Mapi Pharma Ltd Process and intermediates for the preparation of abiraterone acetate
CN102898495B (en) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 Method for preparing abiraterone acetate

Also Published As

Publication number Publication date
WO2013159225A1 (en) 2013-10-31
EP2841444A4 (en) 2015-11-04
EP2841444A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
CA2871314A1 (en) Process for preparation of 17-substituted steroids
ES2624667T3 (en) Procedure for the preparation of estetrol
JP3722835B2 (en) Synthesis of 17- (3-pyridyl) steroids
ES2607852T3 (en) The use of pregnan and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
CN104066744B (en) Process for preparing 17-substituted steroids
EP0312867B1 (en) Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them
US9663550B2 (en) Method for preparing abiraterone acetate
CA2859897A1 (en) Synthesis of abiraterone and related compounds
US10273263B2 (en) Pro-drug forming compounds
BR112013030833B1 (en) process for the preparation of a compound of formula (i) and process for the preparation of estetrol
JP6904519B2 (en) Manufacturing methods and intermediates for synthesizing intermediates for the antitumor drug niraparib
KR102388809B1 (en) Methods for preparing bile acids
AU775831B2 (en) Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
ES2581317T3 (en) Preparation process of abiraterone or abiraterone acetate
ES2741505T3 (en) Procedure for the preparation of abiraterone acetate and its intermediates
WO2020155613A1 (en) Preparation method for ecteinascidin compound and intermediate thereof
EP2917225A1 (en) Process for making abiraterone-3-acetate
WO2014071983A1 (en) Process for making the 17-triflate intermediate of abiraterone-3-acetate
JPS6118559B2 (en)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190423